1. Home
  2. QUIK vs ZNTL Comparison

QUIK vs ZNTL Comparison

Compare QUIK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuickLogic Corporation

QUIK

QuickLogic Corporation

HOLD

Current Price

$15.67

Market Cap

314.2M

Sector

Technology

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$4.86

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUIK
ZNTL
Founded
1988
2014
Country
United States
United States
Employees
51
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
314.2M
289.0M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
QUIK
ZNTL
Price
$15.67
$4.86
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
$11.00
$6.60
AVG Volume (30 Days)
479.1K
1.3M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
$20,112,000.00
N/A
Revenue This Year
$75.17
N/A
Revenue Next Year
$16.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.80
$1.21
52 Week High
$24.33
$6.95

Technical Indicators

Market Signals
Indicator
QUIK
ZNTL
Relative Strength Index (RSI) 38.00 64.59
Support Level $6.10 $3.53
Resistance Level $23.39 $5.11
Average True Range (ATR) 1.61 0.38
MACD -0.64 0.11
Stochastic Oscillator 14.29 81.88

Price Performance

Historical Comparison
QUIK
ZNTL

About QUIK QuickLogic Corporation

QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: